Altiratinib
Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with an HGF antagonist in vitro.
| Catalog Number | T2054 |
| Alternative Name(s) | DCC-2701 |
| Research Area | Tyrosine Kinase/Adaptors|||Angiogenesis |
| Molecular Formula | C26H21F3N4O4 |
| CAS# | 1345847-93-9 |
| SMILES | FC1=CC=C(NC(=O)C2(CC2)C(=O)NC2=CC(F)=C(OC3=CC(NC(=O)C4CC4)=NC=C3)C=C2F)C=C1 |
| Size | 10 mg |
| Supplier Page | https://www.targetmol.com/compound/Altiratinib |
| Additional Information | https://www.targetmol.com/datasheet/T2054 |
